scholarly journals Increasing off-label use of antipsychotic medications in the United States, 1995-2008

2011 ◽  
Vol 20 (2) ◽  
pp. 177-184 ◽  
Author(s):  
G. C. Alexander ◽  
S. A. Gallagher ◽  
A. Mascola ◽  
R. M. Moloney ◽  
R. S. Stafford
Keyword(s):  
United States ◽  
The United States ◽  
Off Label Use ◽  
Antipsychotic Medications ◽  
Off Label ◽  
Label Use

scholarly journals Off-label use of cancer therapies in women diagnosed with breast cancer in the United States

SpringerPlus ◽  
2015 ◽  
Vol 4 (1) ◽  
Author(s):  
Sophie Hamel ◽  
Douglas S McNair ◽  
Nicholas J Birkett ◽  
Donald R Mattison ◽  
Anthony Krantis ◽  
...  
Keyword(s):  
Breast Cancer ◽  
United States ◽  
The United States ◽  
Cancer Therapies ◽  
Off Label Use ◽  
Off Label ◽  
Label Use

Off‐label use of prescription analgesics among hospitalized children in the United States

2020 ◽  
Vol 29 (4) ◽  
pp. 474-481
Author(s):  
Mary Carmack ◽  
Charles Berde ◽  
Michael C. Monuteaux ◽  
Shannon Manzi ◽  
Florence T. Bourgeois
Keyword(s):  
United States ◽  
The United States ◽  
Hospitalized Children ◽  
Off Label Use ◽  
Off Label ◽  
Label Use

Characterization of the Early Years of Bevacizumab Use for First-Line Treatment of Ovarian Cancer in the United States

2021 ◽  
pp. OP.20.00918
Author(s):  
Soledad Jorge ◽  
Barbara A. Goff ◽  
Heidi J. Gray ◽  
Daniel A. Enquobahrie ◽  
Kemi M. Doll
Keyword(s):  
United States ◽  
Ovarian Cancer ◽  
Metastatic Disease ◽  
The United States ◽  
Interquartile Range ◽  
Newly Diagnosed ◽  
Off Label Use ◽  
Off Label ◽  
Factors Associated ◽  
Label Use

PURPOSE: To quantify early dissemination patterns, factors influencing use, and costs of bevacizumab (BEV) for the treatment of newly diagnosed ovarian cancer (OC) in the United States before its regulatory approval for this indication (off-label use). METHODS: We identified women 18-65 years of age with newly diagnosed OC treated with surgery and platinum-based chemotherapy from 2008 to 2016 through the MarketScan database (N = 8,109). The proportion of women receiving BEV over time was calculated, multivariate logistic regression used to determine factors associated with BEV use, and total costs per cycle of chemotherapy with and without BEV abstracted. RESULTS: BEV utilization rose 1.8-fold during the study period, from 4.1% (2008) to 7.4 % (2016). BEV was used with non–platinum/taxane regimens over a third of the time (37.2%). Physician specialty (medical oncology v gyn oncology) and geography (southeast region) were significantly associated with higher rates of use. Clinical factors associated with BEV use were metastatic disease and presence of ascites. The median cost of one cycle of platinum/taxane chemotherapy plus BEV was $10,897 in US dollars (USD) (interquartile range $7,573-$18,133 USD), compared with $1,629 USD (interquartile range, $683.0-$4,461 USD) for platinum/taxane alone. CONCLUSION: Off-label use of BEV for newly diagnosed OC was rare (< 10%), but doubled following presentation of phase II and III data at international meetings. Both clinical (ascites, metastatic disease, and age) and nonclinical (specialty and region) factors were associated with BEV use, and its use was accompanied by a six-fold increase in the cost of one cycle of treatment.

scholarly journals Clinical outcomes with on-label and off-label use of the transcatheter heart valve in the United States

2014 ◽  
Vol 84 (1) ◽  
pp. 124-128 ◽  
Author(s):  
Joel A. Lardizabal ◽  
Conrad J. Macon ◽  
Brian P. O'Neill ◽  
Vikas Singh ◽  
Claudia A. Martinez ◽  
...  
Keyword(s):  
United States ◽  
Clinical Outcomes ◽  
Heart Valve ◽  
The United States ◽  
Off Label Use ◽  
Off Label ◽  
Transcatheter Heart Valve ◽  
Label Use

Off-label use of oral fluoroquinolone antibiotics in outpatient settings in the United States, 2006 to 2012

2016 ◽  
Vol 25 (9) ◽  
pp. 1042-1051 ◽  
Author(s):  
Ziyad S. Almalki ◽  
Abdullah K. Alahmari ◽  
Jeff J. Guo ◽  
Teresa M. Cavanaugh
Keyword(s):  
United States ◽  
The United States ◽  
Off Label Use ◽  
Off Label ◽  
Fluoroquinolone Antibiotics ◽  
Outpatient Settings ◽  
Label Use

scholarly journals National trends in off-label use of atypical antipsychotics in children and adolescents in the United States

Medicine ◽  
2016 ◽  
Vol 95 (23) ◽  
pp. e3784 ◽  
Author(s):  
Minji Sohn ◽  
Daniela C. Moga ◽  
Karen Blumenschein ◽  
Jeffery Talbert
Keyword(s):  
United States ◽  
Children And Adolescents ◽  
Atypical Antipsychotics ◽  
The United States ◽  
Off Label Use ◽  
Off Label ◽  
National Trends ◽  
Label Use
Sign in / Sign up

Export Citation Format

Share Document